Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Characterization of the extent of a large outbreak of Legionnaires' disease by serological assays.

Simonsen Ø, Wedege E, Kanestrøm A, Bolstad K, Aaberge IS, Ragnhildstveit E, Ringstad J.

BMC Infect Dis. 2015 Mar 28;15:163. doi: 10.1186/s12879-015-0903-2.

2.

Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.

Wedege E, Lie K, Bolstad K, Weynants VE, Halstensen A, Herstad TK, Kreutzberger J, Nome L, Naess LM, Aase A.

Scand J Immunol. 2013 Jun;77(6):452-9. doi: 10.1111/sji.12051.

3.

Molecular characterization of clinical and environmental isolates of Legionella pneumophila in Norway, 2001-2008.

Wedege E, Bolstad K, Borgen K, Fritzsønn E, Caugant DA.

Scand J Infect Dis. 2013 Jan;45(1):59-64. doi: 10.3109/00365548.2012.710855. Epub 2012 Sep 19.

PMID:
22992204
4.

Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.

Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Høiby EA, Wallington A, Vipond C, Skehel M, Tang CM, Feavers IM, Wedege E, Wheeler JX.

Vaccine. 2010 Apr 19;28(18):3211-8. doi: 10.1016/j.vaccine.2010.02.023. Epub 2010 Feb 25.

PMID:
20188677
5.

Seroepidemiological study after a long-distance industrial outbreak of legionnaires' disease.

Wedege E, Bergdal T, Bolstad K, Caugant DA, Efskind J, Heier HE, Kanestrøm A, Strand BH, Aaberge IS.

Clin Vaccine Immunol. 2009 Apr;16(4):528-34. doi: 10.1128/CVI.00458-08. Epub 2009 Feb 18.

6.

Detection of measles- and mumps-specific IgG antibodies in paired serum and oral fluid samples from Norwegian conscripts.

Vainio K, Samdal HH, Anestad G, Wedege E, Skutlaberg DH, Bransdal KT, Mundal R, Aaberge IS.

Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):461-5. doi: 10.1007/s10096-008-0460-3. Epub 2008 Feb 22.

PMID:
18293018
7.

Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, Oster P, Martin D.

Clin Vaccine Immunol. 2007 Jul;14(7):830-8. Epub 2007 May 9.

8.
9.
10.

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.

Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E.

Vaccine. 2005 Mar 18;23(17-18):2202-5.

PMID:
15755595
11.

Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide.

Sprong T, Møller AS, Bjerre A, Wedege E, Kierulf P, van der Meer JW, Brandtzaeg P, van Deuren M, Mollnes TE.

Infect Immun. 2004 Jun;72(6):3344-9.

12.

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Wedege E, Kuipers B, Bolstad K, van Dijken H, Frøholm LO, Vermont C, Caugant DA, van den Dobbelsteen G.

Infect Immun. 2003 Jul;71(7):3775-81.

13.

Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant.

Bjerre A, Brusletto B, Mollnes TE, Fritzsønn E, Rosenqvist E, Wedege E, Namork E, Kierulf P, Brandtzaeg P.

J Infect Dis. 2002 Jan 15;185(2):220-8. Epub 2002 Jan 3.

PMID:
11807696
14.

Serological characterization.

Kuipers B, van den Dobbelsteen G, Wedege E, van Alphen L.

Methods Mol Med. 2001;67:131-45. doi: 10.1385/1-59259-149-3:131.

PMID:
21337142
15.

Immunoblot analysis of sera from patients and vaccinees.

Wedege E.

Methods Mol Med. 2001;66:275-88. doi: 10.1385/1-59259-148-5:275.

PMID:
21336761
16.

IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements.

Wedege E, Bolstad K, Wetzler LM, Guttormsen H.

J Immunol Methods. 2000 Oct 20;244(1-2):9-15.

PMID:
11033014
18.

Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread.

Jelfs J, Munro R, Wedege E, Caugant DA.

Clin Diagn Lab Immunol. 2000 May;7(3):390-5.

19.

Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.

Berstad AK, Andersen SR, Dalseg R, Dromtorp S, Holst J, Namork E, Wedege E, Haneberg B.

Vaccine. 2000 Mar 17;18(18):1910-9.

PMID:
10699340
20.

A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.

Berstad AK, Holst J, Frøholm LO, Haugen IL, Wedege E, Oftung F, Haneberg B.

J Med Microbiol. 2000 Feb;49(2):157-63.

PMID:
10670566
21.

The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci.

Toropainen M, Käyhty H, Saarinen L, Rosenqvist E, Høiby EA, Wedege E, Michaelsen T, Mäkelä PH.

Vaccine. 1999 Jun 4;17(20-21):2677-89.

PMID:
10418919
22.

Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice.

Dalseg R, Wedege E, Holst J, Haugen IL, Høiby EA, Haneberg B.

Vaccine. 1999 May 14;17(19):2336-45.

PMID:
10392615
23.

Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.

Wedege E, Caugant DA, Musacchio A, Saunders NB, Zollinger WD.

Clin Diagn Lab Immunol. 1999 Jul;6(4):639-42.

24.

No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.

Wedege E, Nokleby H, Bjune G.

J Infect Dis. 1999 Jul;180(1):242; author reply 242-3. No abstract available.

PMID:
10353890
25.

Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.

Rosenqvist E, Musacchio A, Aase A, Høiby EA, Namork E, Kolberg J, Wedege E, Delvig A, Dalseg R, Michaelsen TE, Tommassen J.

Infect Immun. 1999 Mar;67(3):1267-76.

27.

Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant.

Haneberg B, Dalseg R, Oftung F, Wedege E, Høiby EA, Haugen IL, Holst J, Andersen SR, Aase A, Meyer Naess L, Michaelsen TE, Namork E, Haaheim LR.

Dev Biol Stand. 1998;92:127-33.

PMID:
9554266
28.

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Haneberg B, Dalseg R, Wedege E, Høiby EA, Haugen IL, Oftung F, Andersen SR, Naess LM, Aase A, Michaelsen TE, Holst J.

Infect Immun. 1998 Apr;66(4):1334-41.

29.

Immune responses to linear epitopes on the PorB protein of Neisseria meningitidis in patients with systemic meningococcal disease.

Delvig AA, Wedege E, Michaelsen TE, Høiby EA, Brandtzaeg P, Rosenqvist E.

Microbiology. 1996 Sep;142 ( Pt 9):2491-8.

PMID:
8828216
30.

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J, Klem A, Rønnild E, Bjune G, Nøkleby H.

Infect Immun. 1995 Dec;63(12):4642-52.

31.

Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease.

Idänpään-Heikkilä I, Høiby EA, Chattopadhyay P, Airaksinen U, Michaelsen TM, Wedege E.

J Med Microbiol. 1995 Nov;43(5):335-43.

PMID:
7562997
32.

A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine.

Delvig AA, Wedege E, Caugant DA, Dalseg R, Kolberg J, Achtman M, Rosenqvist E.

Microbiology. 1995 Jul;141 ( Pt 7):1593-600.

PMID:
7551027
33.

Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.

Wedege E, Kolberg J, Delvig A, Høiby EA, Holten E, Rosenqvist E, Caugant DA.

Clin Diagn Lab Immunol. 1995 May;2(3):314-21.

34.

Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population.

Caugant DA, Høiby EA, Magnus P, Scheel O, Hoel T, Bjune G, Wedege E, Eng J, Frøholm LO.

J Clin Microbiol. 1994 Feb;32(2):323-30.

35.

A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.

Rosenqvist E, Høiby EA, Wedege E, Caugant DA, Frøholm LO, McGuinness BT, Brooks J, Lambden PR, Heckels JE.

Microb Pathog. 1993 Sep;15(3):197-205.

PMID:
7505873
36.

The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

Rosenqvist E, Høiby EA, Wedege E, Kusecek B, Achtman M.

J Infect Dis. 1993 May;167(5):1065-73.

PMID:
8486938
37.

Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins.

Wedege E, Dalseg R, Caugant DA, Poolman JT, Frøholm LO.

J Med Microbiol. 1993 Jan;38(1):23-8.

PMID:
7678117
38.

Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Frøholm LO, Lindbak AK, Møgster B, Namork E, Rye U, et al.

NIPH Ann. 1991 Dec;14(2):67-79; discussion 79-80.

PMID:
1812438
39.

Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.

Wedege E, Bjune G, Frøholm LO, Høiby EA, Rosenqvist E.

NIPH Ann. 1991 Dec;14(2):183-4; discussion 185-6. No abstract available.

PMID:
1812431
40.

Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis.

Frøholm LO, Caugant DA, Holten E, Høiby EA, Rosenqvist E, Wedege E.

NIPH Ann. 1991 Dec;14(2):139-43; discussion 144-6. No abstract available.

PMID:
1812428
41.

The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.

Høiby EA, Bjune G, Frøholm LO, Eng J, Halstensen A, Rosenqvist E, Rønnild E, Wedege E.

NIPH Ann. 1991 Dec;14(2):107-21; discussion 121-3.

PMID:
1812424
43.

IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination.

Sjursen H, Wedege E, Rosenqvist E, Naess A, Halstensen A, Matre R, Solberg CO.

APMIS. 1990 Dec;98(12):1061-9.

PMID:
2126441
44.

Serogroup determination of Neisseria meningitidis by whole-cell ELISA, dot-blotting and agglutination.

Rosenqvist E, Wedege E, Høiby EA, Frøholm LO.

APMIS. 1990 Jun;98(6):501-6.

PMID:
2116811
45.

Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA.

Wedege E, Høiby EA, Rosenqvist E, Frøholm LO.

J Med Microbiol. 1990 Mar;31(3):195-201.

PMID:
2107317
47.

Genetic diversity of penicillin G-resistant Neisseria meningitidis from Spain.

Mendelman PM, Caugant DA, Kalaitzoglou G, Wedege E, Chaffin DO, Campos J, Saez-Nieto JA, Viñas M, Selander RK.

Infect Immun. 1989 Apr;57(4):1025-9.

48.

Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents.

Wedege E, Bryn K, Frøholm LO.

J Immunol Methods. 1988 Oct 4;113(1):51-9.

PMID:
2459253
49.

Reactivity with legume lectins of three monoclonal antibodies made against the Lathyrus odoratus lectin.

Kolberg J, Michaelsen TE, Wedege E, Heier HE.

Biol Chem Hoppe Seyler. 1988 May;369(5):365-70.

PMID:
3166740
50.

Supplemental Content

Loading ...
Support Center